STOCK DOWN 8%: WHAT'S BEHIND TEVA'S MASSIVE PLUNGE?
sells Copaxone. Teva's Copaxone patent is expiring in 2014! The clock
on Copaxone's market exclusivity is ticking fast! Plus: New competitors
in the multiple sclerosis treatment market, such as Tecfidera, are
another threat to Copaxone sales. Today, Teva's future is even more
uncertain after its CEO announced his resignation. Click here to see